Dimerix

Kidneys are master filters, but inflammation is their enemy. This Kidney Awareness Month, @dimerixltd endorses the National Kidney Foundation's @nkf advice on managing factors that drive inflammation. More here: kidney.org/news-stories/n… #KidneyAwareness #FSGS #NationalKidneyMonth

Thanks to everyone who joined the @Dimerix investor briefing in Perth this week. It was a pleasure sharing our progress and outlook, and we greatly appreciated the strong engagement and discussion in the room.  We look forward to continuing the conversation! $DXB #ASX #Biotech

Thank you to @EurozHartleys for the opportunity to present at the annual Institutional Conference today. CEO Dr Nina Webster provided attendees with an update on $DXB’s commercial and clinical strategy - presentation here: investors.dimerix.com/investor-centr… #eurozhartleys #lifesciences

@StockheadAU's latest Special Report focuses on Dimerix’s (ASX:DXB) planned blinded review of our Phase 3 ACTION3 study of our lead candidate DMX-200 in focal segmental glomerulosclerosis (FSGS). Read the article here: stockhead.com.au/health/dimerix… #kidneydisease #FSGS #ClinicalTrials

@dimerixltd ($DXB) will conduct a blinded review of its Phase 3 ACTION3 trial data to confirm statistical assumptions for the primary endpoint in late March 2026. More here: investors.dimerix.com//investor-cent… #FSGS #trialmilestone #FSGS

@dimerixltd ($DXB) latest trial milestone has been highlighted by @StockheadAU, reporting that Dimerix has dosed its 333rd & final adult patient in its ACTION3 Phase III trial evaluating DMX-200 for FSGS. Article here: stockhead.com.au/health/dimerix… #FSGS

@dimerixltd ($DXB) has reached a major milestones in its ACTION3 Phase 3 clinical trial for #FSGS, having dosed its final 333rd adult patient. Trial is expected to be completed in March 2028. More here: investors.dimerix.com/investor-centr…

Meet Fiona Mitropoulos, Senior Clinical Trial Associate at @dimerixltd From #patient recruitment to engaging global #trial sites, Fiona keeps our ACTION3 Phase 3 study on track, with a firm focus on delivering a much‑needed #treatment for #FSGS. 🎥➡️ youtu.be/YqY8sc_40gs

Today marks the 115th anniversary of International Women’s Day, recognising continued progress towards gender equality - @Dimerixltd is very proud to support initiatives that advance women in STEM. Learn more about #IWD by visiting: internationalwomensday.com #WomeninSTEM

He drives end‑to‑end product development and is passionate about turning innovative science into real therapies. Get to know Preetam here: youtu.be/DT3S5xVc7yg #MeetTheDimeriXperts #Biotech #DrugDevelopment

📣 @dimerixltd (ASX:DXB) is holding interactive, in-person briefings in Perth and Singapore for investors to hear an update on our clinical and commercial strategy. Read the release for more info and details on how to register: investors.dimerix.com/investor-centr… Places are strictly limited.

In light of #RareDiseaseDay today, we sat down with our Chief Medical Officer, David Fuller and asked some questions. Learn more about rare disease day here: rarediseaseday.org and find out more about Dimerix here: dimerix.com

Did you know? A special regulatory status is granted by the FDA in key territories including the US to companies researching drugs for rare diseases, known as ‘Orphan Drug Designation’ (ODD). Learn more about rare diseases: rarediseaseday.org

@dimerixltd (ASX:DXB) was invited to participate in the @Oppenheimer 36th Annual Healthcare Life Sciences Conference, held in New York and virtually on 27 February 2026. See the full Dimerix presentation here: investors.dimerix.com/investor-centr… #growthinvestors #biotechinvesting #biotech

@dimerixltd (ASX:DXB) has released its Financial Report for the half year ended 31 December 2025, detailing our key operational highlights for the period. You can access the report here: investors.dimerix.com/investor-centr… #biotechinvesting #FSGS #financialreports #ACTION3

Did you know that ‘rare diseases’ are not that rare – over 300 million people worldwide are currently suffering from a rare disease, with over 300,000 people having been diagnosed with a rare disease in Australia alone. Learn more here: rarediseaseday.org

@dimerixltd CEO Dr Nina Webster was interviewed for the 2026 @StockheadAU's Biotech Guide, discussing Dimerix’s commercial and clinical outlook for 2026. More here: stockhead.com.au/investor-guide… #healthcareinvesting #biotechinvestor #biotech #rarediseases #FSGS

🎥 No drug reaches patients without passing her desk! Meet Lesley White, Director of Regulatory Affairs at @dimerixltd She leads global regulatory strategy, turning complex data into compelling stories for approval. Watch here: youtu.be/AZe5uVnmA0o #MeetTheDimeriXperts

A great article from @StockheadAU this morning featuring @dimerixltd (ASX:DXB), on why strategic incentives offered for developing treatments for rare diseases mean they are becoming an attractive proposition for pharmaceutical companies. 🧪 More here: stockhead.com.au/health/asx-hea…

$DXB will participate in a panel event at @wholesaleinvest's Emergence Sydney 2026 next week to discuss "Australian Life Sciences Success Stories and Identifying the next High-Growth Opportunity”. More here: eventbrite.com.au/e/emergence-in… #lifesciences #emergence2026 @MTPConnect_AUS